- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Johnson and Johnson (JNJ)
Track today's live J&J (JNJ) share price, performance and key data on this page with our current NYSE:JNJ stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the J&J share price on the NYSE exchange. Use the dropdown to switch exchange for the JNJ share price, head to our technical summary section, which provides analysis on J&J share price buy/sell indicators using real-time data (or discuss the J&J (JNJ) stock price today with other investors in the J&J NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE:JNJ share price (ISIN: US4781601046) to enhance your trading decisions with our free investment tools and resources.
What Is the Johnson and Johnson Share Price Today?
The J&J share price today is 254.66.
What Is the Stock Symbol for Johnson and Johnson
The stock symbol (or 'ticker') for Johnson & Johnson is "JNJ."
What Stock Exchange Does Johnson and Johnson Trade On?
Johnson & Johnson is listed and trades on the NYSE stock exchange.
Is Johnson and Johnson a Good Stock to Buy?
Determining whether J&J (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NYSE:JNJ share price (ISIN: US4781601046) to enhance your trading decisions with our free investment tools and resources.
What Is the Johnson and Johnson Share Price Today?
The J&J share price today is 254.66.
What Is the Stock Symbol for Johnson and Johnson
The stock symbol (or 'ticker') for Johnson & Johnson is "JNJ."
What Stock Exchange Does Johnson and Johnson Trade On?
Johnson & Johnson is listed and trades on the NYSE stock exchange.
Is Johnson and Johnson a Good Stock to Buy?
Determining whether J&J (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NYSE
Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| JNJ | · | NYSE | · | USD | |
| JNJ | · | Xetra | · | EUR | |
| JNJ | · | Switzerland | · | CHF | |
| JNJUSD | · | Switzerland | · | USD | |
| 1JNJ | · | Milan | · | EUR | |
| JNJ | · | Vienna | · | EUR | |
| DJNJ2m | · | Buenos Aires | · | ARS | |
| DJNJ3m | · | Buenos Aires | · | ARS | |
| JNJm | · | Buenos Aires | · | ARS | |
| JNJB34 | · | B3 | · | BRL | |
| JNJ | · | Toronto | · | CAD | |
| JNJ | · | Mexico | · | MXN | |
| JNJCO | · | Colombia | · | COP | |
| JNJUS | · | Lima | · | USD | |
| JNJ | · | Ukraine | · | UAH | |
| JNJ | · | Frankfurt | · | EUR | |
| JNJ | · | TradeGate | · | EUR | |
| JNJ_KZ | · | KASE | · | USD | |
| JNJ | · | CBOE Canada | · | CAD |
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
247.87
255.11
52 wk Range
151.52
255.11
Unusual trading volume
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
247.87255.11
52 wk Range
151.52255.11
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.10%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.10%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JNJ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
257.50
Upside
+1.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
15 Buy
7 Hold
1 Sell
Ratings:
23 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 257.50
(+1.12% Upside)
Johnson & Johnson SWOT Analysis
Oncology Powerhouse | Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030 |
Financial Resilience | Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability |
Strategic Expansion | J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave |
Analyst Perspectives | Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition |
Johnson & Johnson Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $24.1B (up 6.4% YoY), beating estimates of $23.61B; adjusted EPS of $2.70 topped forecast of $2.68 by 0.75%
- Stelara sales plunged 61.7% due to biosimilar competition, creating major headwind; excluding Stelara, company posted double-digit growth
- Full-year guidance raised on strength in oncology/immunology portfolios and expected momentum from new product launches in MedTech
- Stock declined 0.5% in premarket to $236.78 despite earnings beat, reflecting investor concerns over biosimilar pressures on key products
- U.S. sales grew 8.3% vs international 3.9%; net earnings reached $5.2B as company navigates tariffs and regulatory challenges
Last Updated: 14/04/2026, 14:58
Read Full TranscriptEarnings
Latest Release
14/04/2026
EPS / Forecast
2.70 / 2.68
Revenue / Forecast
24.1B / 23.61B
Compare JNJ to Peers and Sector
Metrics to compare | JNJ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJNJPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.1x | 25.6x | −0.4x | |
PEG Ratio | −7.48 | 0.08 | 0.00 | |
Price/Book | 7.6x | 4.0x | 2.6x | |
Price / LTM Sales | 6.4x | 4.1x | 3.0x | |
Upside (Analyst Target) | 2.8% | 0.0% | 56.9% | |
Fair Value Upside | Unlock | 10.9% | 9.3% | Unlock |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the J&J (NYSE: JNJ) Share Price Today?
The J&J stock price today is 254.66 USD.
What Stock Exchange Does J&J (JNJ) Trade On?
J&J is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for J&J?
The stock symbol (also called a 'ticker') for J&J is "JNJ."
Does J&J Pay Dividends? What’s The Current JNJ Dividend Yield?
Yes, JNJ Pays Dividends to its Shareholders. The current J&J dividend yield is 2.1%.
What Is the Current J&J Market Capitalisation?
As of today, J&J (NYSE: JNJ) market cap is 613.02B USD.
What Is J&J's (JNJ) Earnings Per Share (TTM)?
The J&J EPS is currently 8.64 (Trailing Twelve Months).
When Is the Next J&J Earnings Date?
J&J's next earnings report will be released on 15/07/2026.
Is JNJ a Buy or Sell From a Technical Analyst Perspective?
Based on today's J&J moving averages and other technical indicators, the daily buy/sell signal for JNJ stock is Strong Buy.
How Many Times Has J&J Stock Split?
J&J has split 6 times. (See the JNJ stock split history page for full effective split date and price information.)
How Many Employees Does J&J Have?
J&J has 138200 employees, based on their latest Companies House report.
What is the current trading status of J&J (NYSE: JNJ)?
As of 27/06/2026, J&J (JNJ) is trading at a share price of 254.66 USD, with a previous close of 244.88 USD. The stock has fluctuated within a day range of 247.87 USD to 255.11 USD, while its 52-week range spans from 151.52 USD to 255.11 USD.
What Is J&J (JNJ) Price Target According to Analysts?
The average 12-month price target for J&J is 257.50 USD, with a high estimate of 285 USD and a low estimate of 190 USD. 15 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +1.12% Upside potential.
What Is the JNJ Premarket Price?
JNJ's last pre-market stock price is 247.94 USD. The pre-market share volume is 20,720.00, and the stock has decreased by 3.06, or 1.25%.
What Is the JNJ After Hours Price?
JNJ's last after hours stock price is 254.29 USD, the stock has decreased by -0.37, or -0.15%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.